Citable company snapshot
Alnylam Pharmaceuticals's latest SEC-sourced 2026-06-30 period shows $1.29B in revenue and $164.49M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $1.29B | $1.17B | +10.6% |
| Operating Income | Jun 30, 2026 | $231.44M | $268.64M | -13.8% |
| Net Income | Jun 30, 2026 | $164.49M | $205.99M | -20.1% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $326.72M | $70.50M | +363.4% |
| Free Cash Flow (computed) | Jun 30, 2026 | $292.04M | $48.67M | +500.0% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Jul 30, 2026; accession 0001178670-26-000062.
ALNY company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.